Skip to main content

Regulatory and Washington

  • CRN, ASN honor two researchers for work in supplement industry

    WASHINGTON — The Council for Responsible Nutrition and the American Society for Nutrition on Monday recognized two researchers for their work in the supplement industry.

    Xiang-Dong Wang and Mario Ferruzzi were awarded the Mary Swartz Rose Senior Investigator Award and the Mary Swartz Rose Young Investigator Award, respectively, at ASN’s Scientific Sessions and Annual Meeting.

  • GPhA applauds new IMS Institute report

    WASHINGTON — The main trade group for the generic drug industry is heralding a new cost analysis by the IMS Institute for Healthcare Informatics showing that generic drugs can reduce co-payments by up to 80%.

    According to the analysis, contained in the report “The Use of Medicines in the United States: Review of 2010,” the average co-payment for a generic drug was $6.06 per prescripton last year, compared with $23.65 to $34.77 for preferred and nonpreferred brand drugs.

  • BIO's Rosado joins FMI

    ARLINGTON, Va. — The Food Marketing Institute said Tuesday that it has appointed Robert Rosado as director of government relations.

    According to FMI, Rosado will focus on legislation that impacts supermarkets in the areas of food safety, health care, food deserts and the 2012 Farm Bill.

    “Rob has a broad range of expertise in food and agriculture that will be very helpful to FMI and its members. His background also includes working with federal agencies on many issues related to the food retail industry,” FMI president and CEO Leslie Sarasin said.

  • NACDS launches mobile app for Annual Meeting

    ALEXANDRIA, Va. — The National Association of Chain Drug Stores announced on Tuesday the launch of its 2011 Annual Meeting mobile Web-based application, which is designed to enhance attendees' efficiency and experience at the NACDS Annual Meeting from April 30 to May 3 in Scottsdale, Ariz.

    In addition, the NACDS mobile website, m.NACDS.org, has been updated with information about the Annual Meeting and all 2011 NACDS events.

  • Sigma-Tau OKed to manufacture primary ingredient in Oncaspar

    GAITHERSBURG, Md. — The Food and Drug Administration has given approval to Sigma-Tau Pharmaceuticals to manufacture the main ingredient of a treatment for leukemia, the drug maker said.

    Sigma-Tau was approved to manufacture L-asparaginase, the primary ingredient in the drug Oncaspar (pegaspargase). Sigma-Tau began seeking approval when the previous manufacturer ceased production. The drug is used to treat acute lymphoblastic leukemia, also known as ALL.

  • FDA approves Actemra as arthritis treatment for children

    SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a drug made by Genentech for treating a rare and severe form of arthritis that affects children, Genentech said.

    The biotech company, the U.S. division of Swiss drug maker Roche, announced the FDA approval of Actemra (tocilizumab) for active systemic juvenile idiopathic arthritis. SJIA has the worst long-term prognosis of all varieties of childhood arthritis.

  • Deloitte: Consumers turn to various resources for recall information

    NEW YORK — Consumers that seek timely and detailed information about product recalls look to multiple resources, according to a new Deloitte survey.

  • Taro receives FDA approval for generic Aldara

    HAWTHORNE, N.Y. — The Food and Drug Administration has approved a topical treatment for skin conditions made by Israeli generic drug maker Taro Pharmaceutical Industries.

    Taro announced Monday the approval of imiquimod cream in the 5% strength. The drug is used to treat actinic keratosis and external genital warts, and is a generic version of Graceway Pharmaceuticals’ Aldara.

    Imiquimod cream has annual sales of around $340 million in the United States, according to Taro.

X
This ad will auto-close in 10 seconds